Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05170893

Enrollment

Registered

2021-12-28

Start date

2022-01-17

Completion date

2022-07-26

Last updated

2023-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis

Brief summary

All chronic kidney disease patients, whether on regular hemodialysis or not, are at high risk of cardiovascular diseases. This is mainly due to increased oxidative stress, reduced antioxidants and generalized inflammation. Coenzyme Q10 is a vitamin-like antioxidant synthesized in almost all body cells, and it is also available in many dietary sources. It was observed that chronic kidney disease patients have low plasma levels of Coenzyme Q10. Clinical benefits of Coenzyme Q10 supplementation have been documented for various cardiovascular and neurodegenerative disorders. The investigators believe that Coenzyme Q10 supplementation may have potential benefits in pediatric patients receiving hemodialysis; mainly due to its antioxidant activity and anti-inflammatory effects.

Interventions

DIETARY_SUPPLEMENTCoenzyme Q10

Oral capsules

OTHERPlacebo

Oral capsules

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

2 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Male or female patients with ages between 2 to 18 years old. * Undergoing regular hemodialysis for at least 6 months.

Exclusion criteria

* Patients who weigh less than 10 kg.

Design outcomes

Primary

Measure	Time frame	Description
Change in Malondialdehyde (MDA)	12 weeks	marker of oxidative stress

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026